Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil I Daud

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
BEAM trial: lighting the way ahead?Adil I Daud
The Lancet. Oncology|June 18, 2018
Negative but not futile: MAGE-A3 immunotherapeutic for melanomaAdil I Daud
Immunotherapy|May 21, 2016
Part I: Checkpoint inhibitors in cancer therapyAdil I Daud
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
Melanocytic Neoplasms, IntroductionAdil I Daud
The Lancet. Oncology|January 24, 2018
Revisiting RECIST: the case of treatment beyond progressionAdil I Daud
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Removing the unknown from the carcinoma of unknown primaryAdil I Daud
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2013
Reply to M.-E. Percival et al and L.B. SaltzAdil I Daud
Immunotherapy|June 29, 2016
Part II: Checkpoint inhibitors in cancer therapyAdil I Daud
Cancer Journal (Sudbury, Mass.)|January 24, 2017
Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These DrugsKimberly Loo, Adil I Daud
Cancer Control : Journal of the Moffitt Cancer Center|July 7, 2007
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitorsJade Homsi, Adil I Daud
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
BEAM trial: lighting the way ahead?Adil I Daud
The Lancet. Oncology|June 18, 2018
Negative but not futile: MAGE-A3 immunotherapeutic for melanomaAdil I Daud
Immunotherapy|May 21, 2016
Part I: Checkpoint inhibitors in cancer therapyAdil I Daud
Seminars in Cutaneous Medicine and Surgery|July 25, 2018
Melanocytic Neoplasms, IntroductionAdil I Daud
The Lancet. Oncology|January 24, 2018
Revisiting RECIST: the case of treatment beyond progressionAdil I Daud
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Removing the unknown from the carcinoma of unknown primaryAdil I Daud
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2013
Reply to M.-E. Percival et al and L.B. SaltzAdil I Daud
Immunotherapy|June 29, 2016
Part II: Checkpoint inhibitors in cancer therapyAdil I Daud
Cancer Journal (Sudbury, Mass.)|January 24, 2017
Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These DrugsKimberly Loo, Adil I Daud
Cancer Control : Journal of the Moffitt Cancer Center|July 7, 2007
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitorsJade Homsi, Adil I Daud
Pageof 9